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Abstract
AIM:To investigate the efficacy of 6-mercaptopurine 
(6-MP) in cases of azathioprine (AZA) hypersensitivity 
in patients with inflammatory bowel disease. 
METHODS: Twenty nine previously confirmed Crohn’s 
disease (CD) (n = 14) and ulcerative colitis (UC) 
(n = 15) patients with a known previous (AZA) 
hypersensitivity reaction were studied prospectively. 
The 6-MP doses were gradually increased from 0.5 
up to 1.0-1.5 mg/kg per day. Clinical activity indicies 
(CDAI/CAI), laboratory variables and daily doses of 
oral 5-ASA, corticosteroids, and 6-MP were assessed 
before and in the first, sixth and twelfth months of 
treatment. 
RESULTS: In 9 patients, 6-MP was withdrawn in the 
first 2 wk due to an early hypersensitivity reaction. 
Medication was ineffective within 6 mo in 6 CD 
patients, and myelotoxic reaction was observed in two. 
Data were evaluated at the end of the sixth month in 
12 (8 UC, 4 CD) patients, and after the first year in 9 
(6 UC, 3 CD) patients. CDAI decreased transiently at 
the end of the sixth month, but no significant changes 
were observed in the CDAI or the CAI values at the 
end of the year. Leukocyte counts (P  = 0.01), CRP 
(P  = 0.02), and serum iron (P  = 0.05) values indicated 
decreased inflammatory reactions, especially in the UC 
patients at the end of the year, making the possibility 
to taper oral steroid doses.
CONCLUSION: About one-third of the previously AZA-
intolerant patients showed adverse effects on taking 
6MP. In our series, 20 patients tolerated 6MP, but it 
was ineffective in 8 CD cases, and valuable mainly in 
ulcerative colitis patients.
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
5-aminosalicylate is usually ineffective in the main-
tenance treatment of  steroid induced remission in 
idiopathic inflammatory bowel (IBD) diseases, i.e. 
ulcerative colitis (UC) and Crohn’s disease (CD)[1]. In the 
vast majority of  cases immunosuppressive treatment is 
necessary to maintain the remission. Azathioprine (AZA) 
has been advised in the treatment of  UC and CD since 
the middle of  1960’s[2]. It is worth starting if  the patient 
is corticosteroid resistant (the effective dose does not 
lead to remission) or dependent (discontinuation of  
the corticosteroid causes relapse)[3]. Azathioprine and 
its first metabolite 6-mercaptopurine are effective 
immunomodulators, but contrary to the corticosteroids, 
purine analogues have a late onset of  action[4]. Their 
maximum effect can only be expected after 3-6 mo[5]. 
Azathioprine is offered as first choice, but it can cause 
early hypersensitivity reaction (fever), or gastrointestinal 
side effects (nausea, vomiting, and diarrhoea) in the 
first two weeks in 5%-10% of  patients. In these cases, 
6-mercaptopurine (6-MP) may be effective without side 
effects[6]. However, there are few data about the clinical 
efficacy of  changing the AZA to 6-MP therapy in cases 
having hypersensitivity reactions after the first AZA 
medication.
MATERIALS AND METHODS
Between 2002 and 2005, 29 IBD patients (15 women 
and 14 men) were treated with 6-mercaptopurine due 
to azathioprine hypersensitivity. The drug Purinethol, 
50 mg (Laboratoire GlaxoSmithKline) was approved by 
the National Institute of  Pharmacy. The mean age of  the 
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patient’s was 40.1 years (range 19-66 years), and mean 
time to 6-MP treatment from the IBD diagnosis was 
5.4 years (range 0.1-16.4 years). Fifteen patients had UC 
and 14 patients had CD. Table 1 contains the number 
of  IBD patients in the 3 groups, according to extents, 
fistulas and surgeries. 6-MP test dose (50 mg/d for 
7-10 d) was administered first. The therapy had to be 
discontinued in the first two weeks because of  the same 
or similar hypersensitivity reactions as taking azathioprine 
during the initial doses in 9/29 patients (7/9 UC, 2/9 
CD). Among the 9 patients, 4 had hypersensitivity 
reactions, including fever, and 5 were intolerant due to 
GI side-effects. During the very short interval (7-10 
d) between the AZA start and the appearance of  
adverse events, we did not observe side-effects, such as 
leucopoenia, abnormal LFTs or pancreatitis. Medication 
had to be suspended in 8/20 patients during the first 
6 mo because it was ineffective. Decreasing the CDAI 
score not more than 70, and at least 3 score values in 
the CAI, was considered to be a treatment failure. All of  
them were CD patients; their treatment was continued 
by methotrexate and/or infliximab, if  required.
Twelve patients tolerated 6-mercaptopurine without 
side-effects for more than six months with clinical 
efficiency. Four of  12 had Crohn’s disease, 8/12 had UC. 
During the study 9 patients (6 UC, 3 CD) were treated 
for more than a year. The initial dose of  6-MP was 
50 mg/d and it was increased, if  possible, up to 
1.5 mg/kg per day. The clinical activity, 6-MP and 
corticosteroid (prednisolone, methylprednisolone, 
separately) as well as the laboratory variables of  acute 
inflammatory process were recorded. The medication 
was initiated at the first visit, and follow-up visits after 
the first, third, and sixth, twelfth months after the 
initial therapy. Crohn’s Disease Activity Index (CDAI) 
and Clinical Activity Index of  Ulcerative Colitis (CAI) 
were scored and calculated at each visit. According to 
the calculated values, the actual activity was grouped as 
inactive (1), mild (2), moderate (3) or severe (4). The 
following blood chemistry variables were determined, 
erythrocyte sedimentation rate, hematocrit, white 
cell and platelet counts, blood iron level, CRP, and 
fibrinogen. 
STATA V8 program was used for statistical analysis. 
The repeated measurements of  ANOVA and correlation 
analysis were used. Associations of  variables between 
activity groups were analyzed by one way method of  
ANOVA.
RESULTS
The basel ine means ± SD of  CDAI/CAI, CRP, 
ESR, WBC, platelets, and the changes over time 
demonstrated decreased inf lammatory reactions 
(Table 2). Relationships between time (at six months and 
one year), activity, and laboratory variables are presented 
in Table 3. Results of  the analysis corresponded to 
12 patients at 6 mo (8 UC, 4 CD), and 9 mo (6 UC, 3 
CD) at the end of  the first year (repeated measurement 
of  ANOVA). CDAI decreased significantly only at 
the end of  the sixth month in 4 of  the 12 patients in 
whom 6-MP treatment was successful, but a similar 
decrease could not be demonstrated in the CAI of  UC. 
At the end of  the year, such an alteration could not be 
detected in any of  the activity indices. CRP, referring 
to the severity of  the inflammation, decreased and the 
iron level increased significantly at the end of  the year 
(Table 3). Correlation between the calculated activity 
index numeric values (CDAI, CAI) and laboratory 
variables (correlation analysis) is presented in Table 4. 
The laboratory variables associated with the numeric 
values of  the activity revealed a decrease in the 
inflammatory reaction in UC, but not in CD, due to the 
small number of  CD cases. Besides the amelioration 
of  the inflammatory reaction, the direct suppressive 
effect on the bone marrow may also be associated with 
reductions in the numbers of  leukocytes and platelets. 
Treatment had to be discontinued temporarily in 1 case 
because of  leukopenia at the end of  the year. In another 
case, a significant bone marrow depression developed, 
necessitating surgical intervention (ileal-pouch anal 
anastomosis - IPAA) after drug cessation. Hepatotoxic 
side-effects and pancreatitis were not observed during 
the year. Table 5 shows the correlation between the 
activity groups - inactive (1), mild (2), moderate (3), 
severe (4) - and the values of  laboratory variables in UC 
and CD patients (one way ANOVA). The laboratory 
variables correlated substantially better with the group 
classification than with the activity index numeric values.
The average doses of  6-MP and corticosteroids 
administered at the time of  the visits is presented as 
mg/kg (Figure 1). Prednisolon treatment could be 
omitted and the dose of  methylprednisolon could be 
tapered to one third at the end of  the year. At the end 
of  the first year 5/9 patients (3 UC, and 2 CD) became 
steroid free.
DISCUSSION
Systemic corticosteroid treatment is often needed in 
relapses of  idiopathic inflammatory bowel diseases (UC, 
CD)[7]. The dose depends on the activity of  the disease 
with severe cases treated intravenously[8]. If  the patient 
responds to the intravenous regime, treatement should 
be switched to oral administration, and oral doses 
should be tapered gradually and finally terminated. If  
Table 1  The number of IBD patients in the three groups, 
according to extents, fistulas and surgeries 
Disease No. of patients A B C D E F
Group1 UC 7 1 2 4 - - -
Group1 CD 2 - 2 - - - -
Group2 CD 8 3 2 2 1 8   16
Group3 UC 8 1 - 7 1
Group3 CD 4 - 3 1 - 4 4
           29 4 9   14 1    12    21
UC-A: Distal; UC-B: Left sided; UC-C: Pancolitis; CD-A: Small bowel only; 
CD-B: Colon only; CD-C: Small bowel + colon, CD-D: Upper GI + small 
bowel + colon; CD-E: Number of fistulas; CD-F: Number of surgeries. 
the patient proves to be steroid resistant, or dependent, 
immunosuppress ive t r ea tment i s sug g es ted [9]. 
Azathioprine is recommended first, where it is the most 
frequently used immunosuppressive drug for IBD[10]. An 
oral dose of  1.5-2.5 mg/kg per day is usually effective, 
but requires monitoring[11]. Therapeutic effects and side-
effects of  AZA show great variability among the patients 
due to the various concentrations of  the therapeutic 
and toxic metabolites[12]. The application is hampered 
in 9%-25% of  the patients due to its toxic effects. 
Hypersensitivity reactions (fever), or gastrointestinal 
side effects (nausea, diarrhea), can occur during the first 
weeks of  the treatment[13]. According to McGovern et al, 
imidazole that is cleaved of  the AZA molecule can be 
responsible for the development of  this process[14]. AZA 
is a pro-drug that is converted to 6-MP through a non-
enzymatic step. Further metabolism of  6-MP depends 
on three competing enzyme pathways. Hepatotoxic 
6-methylmercaptopurine (6-MMP) is produced by 
thiopurine methyltransferase (TPMT), a key enzyme 
of  toxic and therapeutic metabolites. Measurement 
of  its activity helps determine individual doses[14,15]. 
Catabolism, via xanthine oxidase (XO), forms inactive 
6-thiouric acid which is eliminated through the urine. 
Metabolism, via hypoxantin-guanin phosphoribosyl 
transferase (HPRT), leads to the formation of  cytoactive 
6-thioguanin nucleotide (6-TGN) that binds to the 
DNA and RNA, and is the active molecule responsible 
for the late side-effects in a dose-dependent manner. 
The proportion of  these three enzymes determines the 
effective 6-TGN level. In case of  low TPMT activity 
(due to enzyme polymorphisms) metabolism shifts to 
the production of  6-TGN, where high concentrations 
are associated with efficacy, but above a certain level 
(> 450 pmol/108 erythrocyte), 6-TGN has a myelotoxic 
effects[16]. Bone marrow depression that is a late toxic 
reaction usually occurs in the first three months[17]. 
Other mechanisms participate in the development of  
this process as well since this side-effect is noticed with 
normal and high TPMT activity. During the occurrence 
of  immunosuppressor activity in IBD, a decrease in 
the number of  lamina propria plasma cells and altered 
function of  the lymphocytes and killer cells is detected. 
According to previous studies that need further 
Table 2  Changes of CDAI/CAI, CRP, ESR, WBC, PLT variables in the third group (mean ± SD)
Disease Months CDAI CAI CRP ESR WBC PLT
UC         0 - 7.8 ± 6.3 16 ± 10 30.4 ± 16.2 9.3 ± 3.3 384 ± 175
UC         3 -          6.9 ± 6 8.3 ± 3.5 28.3 ± 16.5       10.3 ± 4.5 336 ± 119
UC         6 - 6.1 ± 6.7 11 ± 19 31.9 ± 32.7         6.8 ± 2 348 ± 197
UC       12 -          1.1 ± 1 4.6 ± 3.5          27 ± 17.2 6.1 ± 2.6         283 ± 87
CD         0 146 ± 128 - 39.8 ± 26.7 41.3 ± 11.6 9.9 ± 2.7 431 ± 136
CD         3 145 ± 124 - 23.3 ± 10.7 29.2 ± 14.1 7 ± 3         332 ± 66
CD         6         167 ± 68 - 21 ± 15 17.6 ± 28.6 9.9 ± 4.2         317 ± 89
CD       12 46 ± 56 - 6 ± 4          18 ± 14.7 6.2 ± 1.3         247 ± 80
Table 3  Significant changes after six and twelve months of 
6-MP treatment
Variable 6 mo 12 mo
CDAI P = 0. 0144 (n = 4) NS n = 3
CAI NS n = 8 NS n = 6
Leukocyte NS P = 0. 0057
CRP NS P = 0. 0206
Serum iron NS P = 0. 0459
NS: Not significant.
Table 4  Correlation of activity index numbers with the 
laboratory variables
Variable                 CAI/UC       CDAI/CD
Thrombocyte                   P  < 0.001 NS
Serum iron                    P = 0.006 NS
CRP                    P = 0.008 NS
Haematocrit                    P = 0.022 NS
Leukocyte                    P = 0.071 (BS) NS
ESR 1st h                    P = 0.077 (BS) NS
NS: Not significant; BS: Borderline significance. 
Table 5  Correlation between activity groups and laboratory 
variables




Leukocyte 0.0144       0.071 (BS)
Haematocrit 0.0270 NS
Serum iron         0.0808 (BS) NS



























Figure 1  Changes of the 6-MP and oral steroid mean doses. 
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potential for life-threatening side-effects, the drug is 
recommended in cooperating patients only[28].
AZA and 6-MP have been accepted as maintenance 
therapies in IBD, but controversy exists regarding 
optimal dosing and benefits of  therapeutic drug 
monitoring of  metabolites[29]. The AZA baseline dose 
(1 .7 mg/kg per day) proved to be ef fec t ive in 
maintaining remission in a French cohort of  CD 
patients, which was lower than the dose used in clinical 
trials (2.5 mg/kg per day). Nielsen et al in their review 
in the year 2001, suggested a 0.25 ± 0.5 mg/kg daily 
initial (AZA equivalent) dose for the 6-MP, increasing to 
1.0 ± 1.5 mg/kg daily[30]. Su and Lichtenstein, three years 
later, advocated “the optimal dose for the treatment of  
active CD is generally considered 2.5 mg/kg per day for 
azathioprine and 1.5 mg/kg per day for 6-MP”[17]. In our 
AZA intolerant patients, the initial dose was 50 mg/d 
with a stepwise increase after the third and sixth month 
with 25 or 50 mg/d up to 1.5 mg/kg per day according 
to the tolerability of  the patients. The low dose and the 
step up policy may play a role in the poor therapeutic 
response, especially in very active Crohn disease patients 
in the second group.
It is worth starting with 6-MP therapy in patients 
with hypersensitivity reactions to AZA. One third of  the 
patients will be intolerant, and another third will not gain 
any benefit, especially those who had serious active CD. 
However, patients with mild or moderate UC/CD might 
have the advantage of  being able to tolerate the daily 
dose of  more than 1 mg/kg.
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